Image

Sujith R. Kalmadi, MD

Medical Oncologist

Gastrointestinal Malignancies

" He is very knowledgeable and answers all questions. He has a wonderful bedside manner, and is able to give not only a diagnosis, but also many options for treatment. I highly recommend Dr. Kalmadi!"

Dr. Kalmadi joined Ironwood Cancer and Research Centers in 2008 and serves as Chief Medical Officer. After finishing his medical schooling in India, Dr. Sujith Kalmadi completed his residency training and fellowship at the Cleveland Clinic in Cleveland, Ohio.

He then served as academic clinical faculty at the Cleveland Clinic School of Medicine (Lerner School) in Cleveland, Ohio, and subsequently at Baylor College of Medicine in Houston, Texas. During his tenure at these prestigious institutions, he pioneered several novel clinical research trials which have been lauded at national scientific meetings and published in peer reviewed journals.

Dr. Kalmadi is actively involved in the education of medical students and residents from Creighton University School of Medicine and Midwestern University and serves as a Clinical Assistant Professor in Hematology and Medical Oncology at both institutions. He has been selected multiple years by his professional peers as a Top Doc in PHOENIX Magazine.

His areas of clinical and research interests include several solid tumors, gastrointestinal malignancies, and hematological disorders. He has been the principal investigator in several innovative clinical trials across the years, which has led to FDA approval of several lifesaving cancer therapeutics.

He currently resides in Chandler with his wife and three children and enjoys tennis, chess, and racquetball during his spare time. He is board-certified in Internal Medicine, Hematology, and Medical Oncology.

Present Title & Subspecialties

Title

Medical Oncology & Hematology

Subspecialties

Gastrointestinal Malignancies

Education & Training

Medical School

Kasturba Medical College, Mangalore, India

Fellowships

Cleveland Clinic, OH, Hematology & Medical Oncology
Cancers Treated
Certifications & Professional Memberships

  • Board Certified Hematology & Medical Oncology
  • Clinical Instructor – Midwestern Medical School, Glendale, Arizona
  • Reviewer, American Board of Internal Medicine, Medical oncology subspecialty Examination, 2007
  • Outstanding teacher of the year award, Hematology-Oncology fellowship program, Taussig cancer center, Cleveland Clinic, 2007
  • Reviewer, Journal of clinical oncology, 2005
  • Reviewer, Cancer, 2005

Publications

Journal publications:

Afatinib versus Erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-8): an open -label randomized controlled phase 3 trial. Lancet oncology, 2015 Aug: 16 (8): 897-907. Turner et al.  Paloma Study group. Collaborator.

Palbociclib in hormone receptor positive advanced breast cancer.  New England Journal of  Medicine. 2015 Jul 16: 373 (3): 209-19. Soria Et al. Lux Lung 8 investigators. Collaborator.

Predictors of clinical outcomes of resected ampullary adenocarcinoma : a single institution  experience. Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Eur J Surg Oncol 2011 Sep: 37 (9)

Clinical Utility of temozolimide in the treatment of malignant paraganglioma: a preliminary  report. Bravo EL, Kalmadi SR, Gill I. Horm Metab Res. 2009 Sep;41(9):703-6. Epub 2009 Jun 17.

Evolving perspectives of the role of novel agents in androgen independent prostate cancer. 6 Kalmadi S, Raghavan D. Indian J Urol 2008 Jul; 24 (3): 303-8

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the southwest oncology group (swog 9810). Kalmadi, S, Rankin, C, Kraut, M, Jacobs, A, Petrylak, D, Adelstein, D, Keohan, M, Taub, R and Borden, E. Lung Cancer 2008 May; 60 (2):  259-263.

Neoadjuvant Therapy for Hepatocellular Carcinoma: Is There an Optimal Approach? Almhanna, K, Kalmadi, S, Pelley, R, and Kim, R. Oncology; 2007 August; Volume 21, Number 9. Review.

Lenalidomide: the emerging role of a novel targeted agent in malignancies. Kalmadi, S., Baz, R., and Mahindra, A. Drugs Today (Barc). 2007 Feb;43(2):85-95. Review.

Epsilon Aminocaproic Acid reduces transfusion requirement in patients with thrombocytopenic  hemorrhage. Kalmadi, S., Tiu, R., Lowe, C., and Kalaycio, M. Cancer: 2006; Volume 107; Issue 1; 136-40. Original article.

Phase I trial of three-weekly docetaxel, carboplatin and lenalidomide in patients with  advanced solid tumors. Kalmadi, S., Davis, M., Dowlati, A., O’Keefe, S., Cline-Burkhardt, M.,  Pelley, R.J., Borden, E., Dreicer, R., Bukowski, R., and Mekhail, T. Investigational New drugs:  2006. Original article.

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with  advanced  non-small  cell  lung  cancer.  Kalmadi,  S,  Mc’Neill,  G,  Davis,  M,  Peereboom,  D,  Adelstein, D, Mekhail, T. Medical Oncology: 2006; Volume 23, No.3. Original article.

The emerging role of arsenic trioxide as an immunomodulatory agent in the management  of multiple myeloma. Kalmadi, S., and Hussein, M. Acta Haematologica; 2006; Vol. 116, 1-7.  Review.

New biology of lung cancer: Prognostic factors and therapeutic impact: Kalmadi, S., Molecular Oncology Report, 2006.Review.

Should prophylaxis for pneumocystis carinii pneumonia in solid organ transplants ever be  discontinued. Gordon, S., LaRosa, S., Kalmadi, S., Arroliga, A., Avery, R., Truesdell-Larosa, L.,  and Longworth, D.L. Clinical Infectious diseases, 1999; 28 (2); 240-6. Original article.

Books and/or Chapters:

Uncommon tumors of the kidney in “Textbook of uncommon cancers- 3rd edition”. Kalmadi, S., Zhou, M., Novick, A., and Bukowski, R. John Wiley and sons, 2005

Fundamentals of cancer treatment: Effects of chemotherapy on neoplastic cells in “ Cancer in the  spine: comprehensive care for spinal column tumors.” Kalmadi, S., and Raghavan, D.Humana  Press, 2005.

Abstracts:

Analysis of 140 cases with biliary tract cancer (BTC). K. Almhanna, R. Kim, S. Kalmadi, p. Elson, J. Dumot, M. Walsh, M. Henderson, R. J. Pelley. 2008 ASCO GI symposium.

Factors  associated  with  tumor  recurrence  and  5-year  postoperative  survival  in  ampullary carcinoma: Cleveland Clinic Experience. A. Lazaryan, K. Almhanna, P. Elson, S. Kalmadi, D.  Vogt, M. Walsh, M. Henderson, R. Pelley, R. Kim. 2008 ASCO GI symposium.

Is adjuvant radiation plus chemotherapy for resectable pancreatic adenocarcinoma associated  with  improved  survival?  The  Cleveland  Clinic  experience.  R.  E.  Tsao,  K.  Almhanna,  A.  Lazaryan, P. Elson, S. Kalmadi, R. J. Pelley, R. Kim, M. Walsh, M. J. Henderson, D. Vogt

Response to transarterial chemoembolization prior to liver transplantation or hepatic resection in  patients with hepatocellular carcinoma. Almhanna, K, Golshayan, A, Sands, M, Levitin, A, Kim,  R, Pelley, R, and Kalmadi,S.  2007 Annual ASCO meeting. Number 15114.

Nigro  regimen treatment of squamous cell cancer of the anus.Kalmadi, S. Pelley, R, Kay, E,  Saxton, J., Bukowski, R, Kim, R, Lavery, C and Fazio, V. 2007 Annual ASCO meeting. Number  14545.

Phase I trial of docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors.  Kalmadi, S., Davis, M., Dowlati, A., O’Keefe, S., Cline-Burkhardt, M., Pelley, R.J., Borden, E.,  Dreicer, R., Bukowski, R., and Mekhail, T. 2006 annual ASCO meeting. Number 13027

Phase II trial of weekly docetaxel and gemcitabine as first line therapy for patients with advanced  non-small cell lung cancer. McNeill, G., Kalmadi, S., Davis, M., Peereboom, D., Bukowski, R.,  and Mekhail, T. 2006 annual ASCO meeting. Number 17076.

Pilot study of SELDI-TOF in bone marrow failure syndromes. Kalmadi, S., Wu, R., Plasinova, M., Sloan, E., Galili, N., Raza, A., Maciejewski, J. 2005 ASCO annual meeting. Number 6547.

EACA is effective in controlling thrombocytopenic hemorrhage in patients with hematologic  malignancies. Tiu, R., Kalmadi, S., Lowe, C., Sobecks, R., Bolwell, B., Lichtin, A., Kalaycio,  M., Maciejewski, J., Advani, A., Sekeres, M., Pohlman, B. 2005 ASCO annual meeting. Number  6648

A  pilot  application  of  SELDI-TOF  mass  spectrometry  in  Bone  marrow  failure  syndromes.  Kalmadi, S., Wu, R., Nearman, Z., Elson, P., Sekeres, M., and Maciejewski, J. A American  society of Hematology 2005 annual meeting. Number 3421.

Weekly docetaxel-gemcitabine as first line treatment in advanced non-small cell lung cancer:  Preliminary results of a phase II study. Kalmadi, S., Mekhail, T., Adelstein, D., Giannini, C.,  Peereboom, D., Olencki, T., Davis, R, and Bukowski, R. 2004 ASCO annual meeting. Number 7236

EACA  reduces  transfusion  requirements  in  patients  with  thrombocytopenic  hemorrhage.     Kalmadi, S., Tiu, R., Lowe, C., Sobecks, R., Bolwell, B., Lichtin, A., Hussein, M., Maciejewski,  J., Advani, A., Sekeres, M., Andresen, S., Pohlman, B., Elson, P., and Kalaycio, M. American  society of hematology 2004 annual meeting. Number 3938.

 

Honors & Awards

PHOENIX Magazine Top Doctor Award

Outstanding teacher of the year award, Hematology-Oncology fellowship program, Taussig cancer center, Cleveland Clinic, 2007

CV
Videos

Videos

Languages

Location

Chandler I

695 S. Dobson Rd
Chandler, AZ 85224

Hours:

Monday- Friday

8am-5pm

Contact
480-821-2838
480-821-9444
Mesa (Dobson)

1432 S. Dobson Rd. St. 106

Mesa, AZ 85202

Hours:

Monday- Friday

8am-5pm

Contact
480-969-3637
480-969-6568
Reviews for Sujith R. Kalmadi, MD
  • Image
  • Image
  • Image
  • Image
  • Image
  • Image
  • Image
  • Image
  • Image
  • Image
  • Image
  • Image
    pixel